triple glp-1/gip/glucagon receptor agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 Effects of triple GLP-1/GIP/Glucagon agonists.
Description
Conclusion Tirzepatides approval as the first drug for OSA expands treatment options for patients with both obesity and sleep apnea
But the caveat always caveats
July 2024: A study that examined the link between taking semaglutide drugs and suffering eye strokes is in the news
Calcitonin in Metabolic Disease It is difficult to evaluate the role of endogenous calcitonin in metabolic diseases for a number of reasons: 1) only few studies have applied human calcitonin in humans, 2) there are currently no antagonists available which selectively target the monomeric calcitonin receptor (84)
history of excessive alcohol use, alcohol abuse, or alcohol use disorder or history of alcohol-related disorders
Figure 1 presents a flowchart of the study selection process
